DE2801355A1 - COMPLEX COMPOUND FOR THE TREATMENT OF DISORDERS WITH ABNORMAL BLOOD CONSTRUCTIONS - Google Patents
COMPLEX COMPOUND FOR THE TREATMENT OF DISORDERS WITH ABNORMAL BLOOD CONSTRUCTIONSInfo
- Publication number
- DE2801355A1 DE2801355A1 DE19782801355 DE2801355A DE2801355A1 DE 2801355 A1 DE2801355 A1 DE 2801355A1 DE 19782801355 DE19782801355 DE 19782801355 DE 2801355 A DE2801355 A DE 2801355A DE 2801355 A1 DE2801355 A1 DE 2801355A1
- Authority
- DE
- Germany
- Prior art keywords
- compound
- ascorbic acid
- complex
- treatment
- divalent copper
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims description 23
- 230000002159 abnormal effect Effects 0.000 title claims description 4
- 239000008280 blood Substances 0.000 title description 2
- 210000004369 blood Anatomy 0.000 title description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 18
- 238000004820 blood count Methods 0.000 claims description 10
- 229960005070 ascorbic acid Drugs 0.000 claims description 9
- 235000010323 ascorbic acid Nutrition 0.000 claims description 9
- 239000011668 ascorbic acid Substances 0.000 claims description 9
- 239000010936 titanium Substances 0.000 claims description 8
- 239000010949 copper Substances 0.000 claims description 6
- 229910052719 titanium Inorganic materials 0.000 claims description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 4
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 229910052802 copper Inorganic materials 0.000 claims description 4
- 238000002844 melting Methods 0.000 claims description 4
- 230000008018 melting Effects 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 150000003609 titanium compounds Chemical class 0.000 claims 2
- 150000001879 copper Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000032839 leukemia Diseases 0.000 description 5
- 201000009030 Carcinoma Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010015866 Extravasation Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000021642 Muscular disease Diseases 0.000 description 2
- 201000009623 Myopathy Diseases 0.000 description 2
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000036251 extravasation Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 201000003104 endogenous depression Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/62—Three oxygen atoms, e.g. ascorbic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/005—Compounds containing elements of Groups 1 or 11 of the Periodic Table without C-Metal linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/003—Compounds containing elements of Groups 4 or 14 of the Periodic Table without C-Metal linkages
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
Description
28" -öS28 "-öS
PATENTANWALT DR. HANS-GUNTHER EGGERT1 DIPLOMCHEMIKERPATENT ADVOCATE DR. HANS-GUNTHER EGGERT 1 DIPLOMA CHEMIST
5 KÖLN Sl, OBERLÄNDER UFER 905 COLOGNE Sl, OBERLÄNDER UFER 90
Beschreibung Be scription
Die vorliegende Erfindung betrifft eine Komplexverbindung mit kurativer und prophylaktischer Wirkung bezüglich Krankheiten, die bei den daran leidenden Personen zu anormalen Blutbildern führen, etwa Karzinome einschließlich Leukämie und chronische Polyarthritis bei Menschen und Tieren. Blutbilder von Patienten, die an einer Anzahl von Krankheiten, wie Arteriosklerose, manisch depressiver Psychose, endogenen Depressionen, Schizophrenie, cystischer Fibröse, Myopathien, amyotropher lateraler Sklerose leiden, zeigen, daß anormale Blutbilder ebenfalls in diesen Fällen vorhanden sind, wobei die Bilder durch Behandlung mit erfindungsgemäßen Komplexverbindungen normalisiert werden, aus welchem Grunde diese Krankheiten auf dieselbe Behandlung ansprechen können.The present invention relates to a complex compound with curative and prophylactic effects on diseases, which lead to abnormal blood counts in those who have it, such as carcinoma including leukemia and rheumatoid arthritis in humans and animals. Blood counts of patients with a number of diseases, such as arteriosclerosis, manic depressive psychosis, endogenous depression, schizophrenia, cystic fibrosis, Myopathies, suffering from amyotrophic lateral sclerosis, show that abnormal blood counts are also present in these cases are, the images are normalized by treatment with complex compounds according to the invention, for whatever reason these diseases may respond to the same treatment.
Die erfindungsgemäße Verbindung kann auch in der Veterinärmedizin verwendet werden.The compound of the invention can also be used in veterinary medicine.
In der Vergangenheit wurde Karzinom, einschließlich Leukämie und in bestimmten Fällen chronische Polyarthritis mit Cytostatica behandelt, die chemische Verbindungen darstellen, die auf die Zellteilung einwirken und eine außerordentliche Toxizität aufweisen. Die Behandlung ist lang andauernd und aufgrund der Toxizität mit sehr starken Nebenwirkungen behaftet. In the past carcinoma, including leukemia and, in certain cases, rheumatoid arthritis has been used with cytostatics which represent chemical compounds that act on cell division and an extraordinary one Exhibit toxicity. The treatment is long-lasting and, due to its toxicity, has very strong side effects.
Es wird angenommen, daß das Fehlen von Mineralien im menschlichen Gesamtblut für die Existenz von Karzinomen und chronischer Polyarthritis beim Menschen entscheidend ist.It is believed that the lack of minerals in human whole blood contributes to the existence of carcinoma and chronic Polyarthritis in humans is crucial.
809829/0859809829/0859
ORIGINAL INSPECTEDORIGINAL INSPECTED
r:r:
Es wurde nun festgestellt, daß Patienten, die an den obigen Krankheiten leiden, ein normales Blutbild, insbesondere in bezug auf das Elementengleichgewicht, das im Gesamtblutbild bei einem gesunden Menschen gefunden wird, besitzen. Durch spektroskopische Analyse der Gehalte an Elementen im Gesamtblutbild wurde daher ein charakteristisches Bild für Leukämie gefunden, wobei die gleichen Abweichungen von den normalen Gehalten für 13 verschiedene Verbindungen vorhanden sind und die Größe der Abweichungen in bezug zur Schwere der Krankheit steht.It has now been found that patients suffering from the above diseases have normal blood counts, particularly in with respect to the elemental balance found in the whole blood count in a healthy person. By Spectroscopic analysis of the content of elements in the whole blood count was therefore a characteristic picture for leukemia found, with the same deviations from normal levels for 13 different compounds and the magnitude of the deviations is related to the severity of the disease.
Es wurde festgestellt, daß eine Änderung in der Zusammensetzung des Gesamtblutbildes in Richtung auf normale Werte einen verbesserten Krankheitszustand ergibt.It was found that a change in the composition of the whole blood count towards normal values improved one Disease state results.
Die erfindungsgemäße Verbindung ist eine Komplexkombination von Ascorbinsäure, dreiwertigem Titan und zweiwertigem Kupfer, wobei das Verhältnis der Bestandteile des Komplexes 36 Mol Ascorbinsäure : 1 Mol Ti+++ : 6 Mol Cu++ ist.The compound according to the invention is a complex combination of ascorbic acid, trivalent titanium and divalent copper, the ratio of the constituents of the complex being 36 mol ascorbic acid: 1 mol Ti +++ : 6 mol Cu ++ .
Dieser Komplex ist ein brauner amorpher Feststoff mit einem Schmelzpunkt von 17o°C und einem aromatischen Geruch. Er ist in Wasser leicht, in 96 % Äthanol schwer löslich und in Diäthyläther unlöslich.This complex is a brown amorphous solid with a melting point of 170 ° C and an aromatic odor. He is Easily soluble in water, sparingly soluble in 96% ethanol and insoluble in diethyl ether.
Der Metallbestandteil stammt gewöhnlich von den Salzen Ti74 TiCL-, CuSO. und CuCl2F die ohne weiteres disoziierbare physio logische unbedenkliche Salze darstellen.The metal component usually comes from the salts Ti 74 TiCL-, CuSO. and CuCl 2 F represent the easily dissociable physiological harmless salts.
Die neue Verbindung wird gewöhnlich in Form einer wässrigen Lösung oder als Pulver oder Tabletten verabreicht. Eine Ver-The new compound is usually administered in the form of an aqueous solution or as a powder or tablets. A verse
809829/0859809829/0859
ORIGINAL INSPECTEDORIGINAL INSPECTED
2 -J '"■* ': 52 -J '"■ *': 5
abreichung in Tablettenform wird bevorzugt. Die neue Verbindung kann zusammen mit Zusatzstoffen verabreicht werden, beispielsweise in der galenischen Pharmazie oder in anderen Medikamenten verwendete Hilfsstoffe, die die erfindungsgemäße Verbindung nicht in nachteiliger Weise beeinflussen. Orale Verabreichung ist geeignet.Administration in tablet form is preferred. The new compound can be administered together with additives, for example in galenic pharmacy or in other medicaments used adjuvants which the invention Do not adversely affect connection. Oral administration is suitable.
Für den erwachsenen Patienten ist beispielsweise eine tägliche Dosis an erfindungsgemäßer Verbindung von 1oo bis 2oo mg geeignet. For the adult patient, for example, a daily dose of a compound according to the invention of 100 to 200 mg is suitable.
Durch Behandeln eines Patienten,"der an Leukämie leidet, mit 2oo mg des erfindurigsgemäßen Komplexes pro Tag als einzige Behandlung wurde der Patient entgegen aller Erfahrungen zwei Jahre am Leben gehalten. Eine beträchtliche Verbesserung des allgemeinen Zustandes und eine Verbesserung der Ergebnisse der spektroskopischen Analyse wurde erhalten.By treating a patient "suffering from leukemia" with 200 mg of the complex according to the invention per day as the only treatment contrary to all experience, the patient was kept alive for two years. A significant improvement on the general condition and an improvement in the results of the spectroscopic analysis were obtained.
Durch wiederholte Versuche mit Mäusen, die an Leukämie litten, wurden außerordentlich positive Resultate durch Behandlung mit der erfindungsgemäßen Verbindung erhalten, die Sterblichkeit von Vergleichsgruppen war zwei- bis dreimal größer als die Sterblichkeit der behandelten Gruppen.Repeated experiments on mice suffering from leukemia have shown extraordinarily positive results from treatment with obtained the compound of the invention, the mortality of comparison groups was two to three times greater than that Mortality of Treated Groups.
Nach Behandlung während drei bis vier Monaten mit der erfindungsgemäßen Verbindung zeigten drei Patienten, die an chronischer Polyarthritis litten, eine merKLiche Normalisierung bezüglich des Blutbildes und alle zeigten eine merkliche Verbesserung in Form von stark reduzierten Schmerzen.After treatment for three to four months with the invention In connection with this, three patients suffering from rheumatoid arthritis showed a noticeable normalization in relation to this the blood count and all showed a noticeable improvement in the form of greatly reduced pain.
809829/0859809829/0859
ORIGINAL INSPECTEDORIGINAL INSPECTED
2 S:: ■2 S :: ■
Nach Behandlung mit der erfindungsgemäßen Verbindung zeigte ein Patient, der an Myopathie litt, eine merkliche Normalisierung des Blutbildes.After treatment with the compound of the invention, a patient suffering from myopathy showed a marked normalization the blood count.
Eine Maus, die unter schwerer abdominaler Flüssigkeitsextravasation aufgrund von Krebs litt ^festgestellt durch Sezieren) wurde mit der erfindungsgemäßen Verbindung behandelt. Nach 14 Tagen war die Extravasation vollständig verschwunden.A mouse undergoing severe abdominal fluid extravasation Suffered from cancer (found by dissection) was treated with the compound of the invention. After 14 Days the extravasation was completely gone.
Zwei Mäuse, die beide unter einem 2 χ 2 cm Brustkarzinom litten (durch Biopsy festgestelltes Ärdenokarzinom),· wurden mit der erfindungsgemäßen Verbindung 13 Wochen behandelt. Der Tumor der ersten Maus konnte nach diesen 13 Wochen makroskopisch nicht mehr entdeckt werden, während der Tumor der zweiten Maus auf 1 χ 1 cm geschrumpft war.Two mice both suffering from 2 χ 2 cm breast carcinoma (Ardenocarcinoma detected by Biopsy), · were with the inventive Compound treated for 13 weeks. The tumor of the first mouse could no longer be detected macroscopically after these 13 weeks while the tumor of the second mouse had shrunk to 1 χ 1 cm.
Die Herstellung der erfindungsgemäßen Verbindung wird anhand der nachstehenden Beispiele erläutert.The preparation of the compound according to the invention is based on the examples below.
12,8 ml 15%iges Ti5(SO4)-. und 15 g CuSO- . 5H^O wurden einer wässrigen Lösung von 63 g konzentrierter Ascorbinsäure zugesetzt. 12g BaO wurden dann zum Niederschlagen der Sulfationen zugesetzt. 12.8 ml of 15% Ti 5 (SO 4 ) -. and 15 g CuSO-. 5H ^ O was added to an aqueous solution of 63 g of concentrated ascorbic acid. 12g BaO was then added to precipitate the sulfate ions.
Die Mischung wurde gerührt und der resultierende Niederschlag abgefiltert, worauf das Filtrat unter Vakuum verdampft wurde, um eine braune amorphe wasserlösliche Verbindung mit einem Schmelzpunkt von 17o°C zu liefern.The mixture was stirred and the resulting precipitate filtered off, whereupon the filtrate was evaporated in vacuo, to provide a brown amorphous water-soluble compound with a melting point of 170 ° C.
809829/0859809829/0859
ORIGINAL INSPECTEDORIGINAL INSPECTED
Eine Lösung von 1o ml 15 %igem TiCl3, 63 g Ascorbinsäure und 1o,2 g CuCl2 . 2Η~Ο in Wasser wurde hergestellt und 16,8 g Ag2O wurde der resultierenden Lösung zugesetzt und der gebildete Niederschlag abfiltriert. Das Filtrat wurde gefriergetrocknet, um einen braunen amorphen Feststoff mit einem Schmelzpunkt von 17o°C zu liefern.A solution of 10 ml of 15% TiCl 3 , 63 g of ascorbic acid and 10.2 g of CuCl 2 . 2Η ~ Ο in water was prepared and 16.8 g of Ag 2 O was added to the resulting solution and the precipitate formed was filtered off. The filtrate was freeze dried to provide a brown amorphous solid with a melting point of 170 ° C.
Der erhaltene Feststoff ist stabil, jedoch ist eine wässrige Lösung der Verbindung unstabil. Die nach den Beispielen hergestellte Verbindung ist eine Komplexverbindung, so daß das Kupferion nicht mit Ammoniak ausgefällt werden kann.The solid obtained is stable, but an aqueous solution of the compound is unstable. The one produced according to the examples Compound is a complex compound so that the copper ion cannot be precipitated with ammonia.
809829/0859809829/0859
Claims (4)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1816/77A GB1549524A (en) | 1977-01-17 | 1977-01-17 | Composition for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2801355A1 true DE2801355A1 (en) | 1978-07-20 |
| DE2801355C2 DE2801355C2 (en) | 1986-11-06 |
Family
ID=9728526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2801355A Expired DE2801355C2 (en) | 1977-01-17 | 1978-01-13 | Complex compound of ascorbic acid, trivalent titanium and divalent copper |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JPS6045638B2 (en) |
| DE (1) | DE2801355C2 (en) |
| FR (1) | FR2377393A1 (en) |
| GB (1) | GB1549524A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0049486A1 (en) * | 1980-10-04 | 1982-04-14 | Byk Gulden Lomberg Chemische Fabrik GmbH | Metal complexes for use in the treatment of cancer |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0046409A1 (en) * | 1980-08-20 | 1982-02-24 | Erwin Günther Walliczek | A process for the preparation of a solution of a cuprous complex; solutions of the cuprous complexes for use in the therapeutic treatment of the human or animal body; and a method of therapeutic treatment of a plant |
| HU183536B (en) * | 1981-08-04 | 1984-05-28 | Nitrokemia Ipartelepek | Process for preparing feed additive or feed promoting the weight increase of domestic animals |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR805335A (en) * | 1935-10-10 | 1936-11-17 | Preparation and isolation of compounds of ascorbic acid and its oxidation products with metals liable to give complex salts | |
| FR807877A (en) * | 1935-10-10 | 1937-01-23 | Preparation and isolation of complex salts of ascorbic acid and its oxidation products |
-
1977
- 1977-01-17 GB GB1816/77A patent/GB1549524A/en not_active Expired
-
1978
- 1978-01-13 DE DE2801355A patent/DE2801355C2/en not_active Expired
- 1978-01-17 FR FR7801246A patent/FR2377393A1/en active Granted
- 1978-01-17 JP JP53002839A patent/JPS6045638B2/en not_active Expired
Non-Patent Citations (1)
| Title |
|---|
| NICHTS-ERMITTELT * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0049486A1 (en) * | 1980-10-04 | 1982-04-14 | Byk Gulden Lomberg Chemische Fabrik GmbH | Metal complexes for use in the treatment of cancer |
| WO1990006749A1 (en) * | 1980-10-04 | 1990-06-28 | Keller Heimo J | Metal complexes having an antineoplastic action, and medicaments containing these complexes |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2377393B1 (en) | 1981-07-31 |
| FR2377393A1 (en) | 1978-08-11 |
| JPS6045638B2 (en) | 1985-10-11 |
| GB1549524A (en) | 1979-08-08 |
| DE2801355C2 (en) | 1986-11-06 |
| JPS53111056A (en) | 1978-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AT395798B (en) | METHOD FOR PRODUCING A MIXTURE FROM PHYSIOLOGICALLY APPLICABLE COMPOUNDS | |
| DE2501787C2 (en) | ||
| DE3152175C2 (en) | ||
| DE1617528B1 (en) | Medicinal preparations for the treatment of diseases of the fundus | |
| DE2604481C2 (en) | ||
| DE2060601B2 (en) | Food supplements | |
| DE2801355C2 (en) | Complex compound of ascorbic acid, trivalent titanium and divalent copper | |
| DE3619426A1 (en) | AGENT FOR INCREASING RESISTANCE TO COLD DISEASES IN PATIENTS WITH RESTRICTED LUNG FUNCTION | |
| EP0349797B1 (en) | Stabilized pharmaceutical composition containing n-acetylcystein | |
| EP1001756B1 (en) | Synergistically acting compositions for selectively combating tumor tissue | |
| EP0207193A2 (en) | Synergetic combination of flupirtin and 4-acetamido-phenol | |
| DE1768655B2 (en) | ||
| DE1617306C3 (en) | Dentifrices for preventing dental disease | |
| DE2352618C3 (en) | PERORALLY OR RECTALLY ADMINISTRATIVE MEDICINE FOR THE TREATMENT OF PARKINSONISM | |
| EP0334177B1 (en) | Pharmaceutical product for oral administration, particularly for the iron and magnesium substitution therapy | |
| DE3700379A1 (en) | PRESERVED EYE DROPS WITH A CROMOGLICIC ACID CONTENT | |
| DE3134709A1 (en) | ANTINEOPLASTIC TITANIUM COMPOUND AND MEDICINAL PRODUCTS CONTAINING THEM | |
| US4211712A (en) | Complex compound for the treatment of diseases disclosing abnormal blood pictures | |
| DE2716535B2 (en) | Use of D-Glucaro-13-lactam | |
| EP0667154A1 (en) | Use of flavolignans as adjuvants in the therapy of tumors | |
| CH634546A5 (en) | METHOD FOR PRODUCING COMPLEX COMPOUNDS OF AMINODICARBONIC ACIDS WITH MAGNESIUM AND HALOGENS. | |
| DE1944906A1 (en) | Erythromycin aliphatic sulfates | |
| DE2901914C2 (en) | Zinc salt of 6-N-acetylamino-caproic acid, process for its preparation and pharmaceuticals containing this compound | |
| EP0098475A2 (en) | Pharmaceutical composition, its manufacture and use | |
| DE2448428A1 (en) | DIURETIC AGENTS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition |